This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Albireo Pharma Toekomstige groei
Future criteriumcontroles 2/6
Belangrijke informatie
64.2%
Groei van de winst
62.9%
Groei van de winst per aandeel
Biotechs winstgroei | 35.0% |
Inkomstengroei | 51.4% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | 02 Mar 2023 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2025 | 267 | 20 | N/A | N/A | 4 |
12/31/2024 | 142 | -91 | N/A | N/A | 4 |
12/31/2023 | 64 | -142 | N/A | N/A | 6 |
12/31/2022 | 35 | -163 | N/A | N/A | 6 |
9/30/2022 | 57 | -131 | -116 | -115 | N/A |
6/30/2022 | 51 | -36 | -114 | -113 | N/A |
3/31/2022 | 45 | -33 | -109 | -108 | N/A |
12/31/2021 | 41 | -34 | -108 | -108 | N/A |
9/30/2021 | 11 | -48 | -122 | -122 | N/A |
6/30/2021 | 9 | -136 | -121 | -120 | N/A |
3/31/2021 | 9 | -120 | -112 | -112 | N/A |
12/31/2020 | 8 | -108 | -101 | -101 | N/A |
9/30/2020 | 12 | -90 | -85 | -85 | N/A |
6/30/2020 | 11 | -82 | -73 | -73 | N/A |
3/31/2020 | 11 | -78 | -64 | -63 | N/A |
12/31/2019 | 10 | -63 | -53 | -53 | N/A |
9/30/2019 | 4 | -71 | -51 | -51 | N/A |
6/30/2019 | 3 | -63 | -47 | -47 | N/A |
3/31/2019 | 2 | -61 | -41 | -41 | N/A |
12/31/2018 | 13 | -46 | -27 | -27 | N/A |
9/30/2018 | 12 | -35 | -25 | -25 | N/A |
6/30/2018 | 12 | -28 | -20 | -20 | N/A |
3/31/2018 | 11 | -19 | -18 | -18 | N/A |
12/31/2017 | 0 | -24 | -28 | -28 | N/A |
9/30/2017 | 3 | -31 | -26 | -26 | N/A |
6/30/2017 | 3 | -28 | -25 | -25 | N/A |
3/31/2017 | 11 | -20 | -15 | -15 | N/A |
12/31/2016 | 11 | -16 | -9 | -9 | N/A |
9/30/2016 | 13 | -5 | -1 | -1 | N/A |
6/30/2016 | 13 | -4 | N/A | 1 | N/A |
3/31/2016 | 5 | -8 | N/A | -5 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: BDQM is forecast to remain unprofitable over the next 3 years.
Winst versus markt: BDQM is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: BDQM is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: BDQM's revenue (51.4% per year) is forecast to grow faster than the German market (3.3% per year).
Hoge groei-inkomsten: BDQM's revenue (51.4% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if BDQM's Return on Equity is forecast to be high in 3 years time